Definitive re-irradiation using intensity-modulated radiation therapy in cancers of the head and neck, focusing on rare tumors
Definitive re-irradiation using intensity-modulated radiation therapy in cancers of the head and neck, focusing on rare tumors
复制标题
DOI：
10.1080/00016489.2018.1438662
复制
发表时间：
2018-01-01
影响因子：
1.4
通讯作者：
Oh, Ryoong-Jin
中科院分区：
文献类型：
--
作者：
Doi, Hiroshi;Uemoto, Kenji;Oh, Ryoong-Jin
目的：为了分析以下的结果再次照射局部复发的罕见的头和颈部tumors.Material和方法：我们回顾性分析了11例接受调强放射治疗（IMRT）的复发肿瘤在头和颈部除了咽喉。结果：原发肿瘤部位包括上颌窦，鼻腔，外耳道，分别在6，3，和2例。中位随访时间为13（范围，3-54）个月。中位生存时间为17个月，1年和2年生存率分别为63.64%和39.77%。在11例患者中，5例在随访期间发生局部失败。1年和2年局部控制率分别为58%和47%。接受放射剂量≥ 3戈伊/次的患者局部控制率明显优于接受较少剂量的患者（p = 0.0419）。1例患者发生3级面部疼痛（急性毒性）。晚期毒性包括放射学检查结果的部分中枢神经系统坏死的3例患者和3级骨坏死和3级面神经疾病的patient.Conclusions：重新照射罕见的头部和颈部肿瘤局部区域复发IMRT可能是一个可以接受的治疗选择。
Purpose: To analyze the outcomes following re-irradiation for local recurrence of rare head and neck tumors.Material and methods: We retrospectively analyzed 11 patients who had received intensity-modulated radiation therapy (IMRT) for recurrent tumors in the head and neck except for laryngopharynx.Results: Primary tumor sites included the maxillary sinus, nasal cavity, and external ear canal in six, three, and two patients, respectively. The median follow-up times were 13 (range, 3-54) months. The median survival time was 17 months with 1- and 2-year survival rates of 63.64 and 39.77%, respectively. Among 11 patients, five experienced local failure in the follow-up period. The 1- and 2-year local control rates were 58 and 47%, respectively. Patients who had received a radiation dose of >= 3 Gy per fraction showed significantly better local control than those receiving less (p = .0419). One patient experienced Grade 3 facial pain as acute toxicity. Late toxicities included radiographic findings of partial central nervous system necrosis in three patients and Grade 3 osteonecrosis and Grade 3 facial nerve disorder in one patient.Conclusions: Re-irradiation of rare head and neck tumors using IMRT for loco-regional recurrence may be an acceptable treatment option.